Top

Published in:

01-08-2020 | Lymphoma | Original Communication

Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature

Authors: D. Marastoni, L. Africa, A. Peretti, S. Bocci, L. Insana, S. Ferrari, F. Ginanneschi, G. Zanette, G. M. Fabrizi, F. Giannini

Published in: Journal of Neurology | Issue 8/2020

Abstract

Introduction

Chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA) is a rare disorder for which the pathological, neurophysiological, and therapeutic evidence remains anecdotal and controversial.

Methods

This report on CANDA focuses on the neurophysiological patterns and treatment responses shared by two cases. One patient underwent nerve ultrasound follow-up. A comprehensive review of the literature highlighted the diverse experiences with different treatment options.

Results

Response to different therapies was similar in both patients: intravenous immunoglobulins achieved a favorable response albeit with significant wearing-off fluctuations; treatment with subcutaneous immunoglobulins (SCIg) was an effective alternative leading to a clinical response for at least 2 years. Rituximab, which was trialed in both patients, was not continued long enough to determine its efficacy in modifying the disease course and/or modulating responsiveness to immunoglobulins. Steroids caused clinical worsening in both patients.

Conclusions

Immunoglobulin therapy appeared as the most effective in the treatment of these two patients. SCIg provided an effective treatment option for the long-term management of CANDA.

Available only for authorised users

Willison HJ, O'Leary CP, Veitch J et al (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124:1968–1977PubMed

Yuki N, Uncini A (2014) Acute and chronic ataxic neuropathies with disialosyl antibodies: a continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve 49(5):629–635PubMed

Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, Hitoshi S, Kanazawa I (1997) Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve 20(7):840–845PubMed

Liu JX, Willison HJ, Pedrosa-Domellöf F (2009) Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 50(7):3226–3232PubMed

Plomp JJ, Willison HJ (2009) Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol 587:3979–3999PubMedPubMedCentral

Gong Y, Tagawa Y, Lunn MP et al (2002) Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 125:2491–2506PubMed

Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41:617–618

Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst 15(1):1–9

Fabrizi GM, Tamburin S, Cavallaro T et al (2018) The spectrum of Charcot–Marie–Tooth disease due to myelin protein zero: an electrodiagnostic, nerve ultrasound and histological study. Clin Neurophysiol 129(1):21–32PubMed

10.

Franciotta D, Gastaldi M, Benedetti L et al (2017) Diagnostics of dysimmune peripheral neuropathies. Neurol Sci 38(Suppl 2):243–247PubMed

11.

McKelvie PA, Gates PC, Day T (2013) Canomad: report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade? Muscle Nerve 48(4):599–603PubMed

12.

Obi T, Murakami T, Takatsu M et al (1999) Clinicopathological study of an autopsy case with sensory-dominant polyradiculoneuropathy with antiganglioside antibodies. Muscle Nerve 22(10):1426–1431PubMed

13.

Yuki N, Miyatani N, Sato S et al (1992) Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAc beta 1–4(Gal3-2 alpha NeuAc8-2 alpha NeuAc)beta 1 configuration. Neurology 42(3 Pt 1):686–689PubMed

14.

Kam C, Balaratnam MS, Purves A et al (2011) Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve 44(5):829–833PubMed

15.

Arbogast SD, Khanna S, Koontz DW, Tomsak RL, Katirji B, Leigh RJ (2007) Chronic ataxic neuropathy mimicking dorsal midbrain syndrome. J Neurol Neurosurg Psychiatry 78(11):1276–1277PubMedPubMedCentral

16.

Garcia-Santibanez R, Zaidman CM, Sommerville RB, Lopate G, Weihl CC, Pestronk A (2018) CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). J Neurol 265(6):1402–1409PubMed

17.

Clark AJ, Kaller MS, Galino J, Willison HJ, Rinaldi S, Bennett DLH (2017) Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain 140(4):898–913PubMedPubMedCentral

18.

Telleman IA, Grimm A, Goedee S, Visser LH, Zaidman CM (2018) Nerve ultrasound in polyneuropathies. Muscle Nerve 57(5):716–728PubMed

19.

Attarian S, Boucraut J, Hubert AM et al (2010) Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 81(1):61–64PubMed

20.

Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C (2010) Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol 257(4):655–657PubMed

21.

Löscher WN, Woertz A, Wallnöfer M, Wanschitz JV, Luef G (2013) Successful treatment of CANOMAD with IVIg and rituximab. J Neurol 260(4):1168–1170PubMed

22.

Krenn M, Keir G, Wieshmann UC (2014) CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg). BMJ Case Rep. https://doi.org/10.1136/bcr-2013-202545 CrossRefPubMedPubMedCentral

23.

Lehmann HC, Hartung HP (2011) Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 231:61–69PubMed

24.

Halstead SK, O'Hanlon GM, Humphreys PD et al (2004) Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127(Pt 9):2109–2123PubMed

25.

McGonigal R, Rowan EG, Greenshields KN et al (2010) Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133:1944–1960PubMed

26.

Sala TP, Crave JC, Duracinsky M, Lepira Bompeka F, Tadmouri A, Chassany O, Cherin P (2018) Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases. Autoimmun Rev 17(9):873–881PubMed

27.

Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD (2009) Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 158(Suppl 1):51–59PubMedPubMedCentral

28.

Racosta JM, Sposato LA, Kimpinski K (2017) Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve 55(6):802–809PubMed

29.

van Schaik IN, Bril V, van Geloven N et al (2018) Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17:35–46PubMed

30.

Nobile-Orazio E, Gallia F, Terenghi F, Bianco M (2017) Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. Expert Rev Neurother 17(8):755–765PubMed

31.

Cocito D, Merola A, Romagnolo A et al (2016) Subcutaneous immuno-globulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry 87(7):791–793PubMed

32.

Siddiqui K, Cahalane E, Keogan M, Hardiman O (2003) Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies. Neurology 61(9):1307–1308PubMed

33.

Boussaïd I, Bouhour F, Vial C, Caudie C (2011) Identification and characterization of a monoclonal IgM reacting with disialylated gangliosides recognizing the CANOMAD syndrome. Ann Biol Clin (Paris) 69(4):476–480

34.

Delval A, Stojkovic T, de Sèze J et al (2004) Ataxic neuropathy associated with disialosylated antibodies: description of new clinical and biochemical forms. Rev Neurol (Paris) 160(10):910–916

35.

Sanvito L, Rajabally YA (2011) Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve 44(3):451–455PubMed

36.

Paradas C, Morgado Y, Gallardo E, Juarez C, Rojas-Garcia R (2011) Prednisone can worsen ataxic neuropathy with anti-disialosyl IgM antibodies. Muscle Nerve 44(5):839–841PubMed

37.

Serrano-Munuera C, Rojas-García R, Gallardo E et al (2002) Antidisialosyl antibodies in chronic idiopathic ataxic neuropathy. J Neurol 249:1525–1528PubMed

38.

Johnson K, Malkan A, Shaffi M (2015) Facial involuntary movements and respiratory failure in CANOMAD, responsive to IVIG therapy. Case Rep Med 2015:170543PubMedPubMedCentral

39.

Iorio R, Capone F, Iannaccone E, Willison HJ, Modoni A, Tonali PA, Silvestri G (2009) SIADH in a patient with sensory ataxic neuropathy with anti-disialosyl antibodies (CANOMAD). J Neurol 256(7):1177–1179PubMed

40.

Taguchi Y, Takashima S, Kusunoki S, Asaoka E, Inoue H (2003) Chronic sensory ataxic neuropathy with polyclonal IgM reactivity to various disialosyl gangliosides. Muscle Nerve 28(1):128–129PubMed

41.

Delval A, Stojkovic T, Vermersch P (2006) Relapsing sensorimotor neuropathy with ophthalmoplegia, antidisialosyl antibodies, and extramembranous glomerulonephritis. Muscle Nerve 33(2):274–277PubMed

42.

Shihashi G, Yagi T, Suzuki S et al (2015) Immune-mediated neuropathy with anti-disialosyl IgM antibodies in diffuse large B-cell lymphoma: a case report and literature review. Intern Med 54(13):1647–1651PubMed

43.

Barnett MH, Barnett Y, Burke D, Willison H (2011) Neurological picture. Spinal nerve root hypertrophy in chronic ataxic neuropathy with antiglycolipid IgM antibodies. J Neurol Neurosurg Psychiatry 82(1):97PubMed

44.

Furiya Y, Hirano M, Kusunoki S, Ueda M, Sugie K, Nishiwaki T, Ueno S (2008) Complete recovery of an aged patient with Guillan–Barré syndrome associated with multiple IgM anti-ganglioside antibodies. Muscle Nerve 38(6):1630–1633PubMed

45.

Umehara F, Kore-Eda Y, Arime T, Kubota R, Arimura K, Osame M (1997) Chronic sensory ataxic neuropathy and ophthalmoplegia with oculomotor nerve hypertrophy associated with IgM antibodies against gangliosides containing disialosyl groups. J Neurol Neurosurg Psychiatry 62(6):673–674PubMedPubMedCentral

Title: Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature
Authors: D. Marastoni
L. Africa
A. Peretti
S. Bocci
L. Insana
S. Ferrari
F. Ginanneschi
G. Zanette
G. M. Fabrizi
F. Giannini
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keyword: Lymphoma
Published in: Journal of Neurology / Issue 8/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09843-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2020

Wiktor Stein (1899–1979)

Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review

Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

Acute transverse myelitis after COVID-19 pneumonia

Correction to: Endovascular stroke treatment’s impact on malignant type of edema (ESTIMATE)

Contributions to the study of spinocerebellar ataxia type 38 (SCA38)